Regulatory Submission

« Back to Glossary Index

What it is

Regulatory Submission is the formal package you send to a regulator or Notified Body to place a device on the market. It explains what the device does, how it works, and why it is safe and effective—using structured evidence, clear claims, and traceable records. It anchors your market authorization or CE marking and must match your QMS and labeling.

Evidence-drivenDevice claims & riskMarket access

Regulatory framework

  • United States (FDA): 510(k) clearance (21 CFR 807 Subpart E); De Novo classification (21 CFR 860 Subpart D); PMA approval (21 CFR 814); IDE for clinical studies (21 CFR 812); labeling/UDI (21 CFR 801, 830); QMSR/820 applies to design and manufacturing.
  • European Union (MDR/IVDR): Technical documentation (Annex II–III); conformity assessment routes and CE marking (MDR Annex IX–XI; IVDR Annex IX–XI); clinical evaluation/PMCF (MDR Art. 61; Annex XIV); GSPRs (Annex I); UDI/EUDAMED (Arts. 27–31).
  • Core standards: ISO 13485 (QMS), ISO 14971 (risk), IEC 62366-1 (usability), IEC 62304/IEC 82304-1 (software), and relevant product standards (e.g., IEC 60601 series).

Key elements

  • Intended use/purpose & indications: Precise, testable claims that drive class and evidence.
  • Device description: Design, materials, software/algorithms, accessories, variants, and manufacturing overview.
  • Risk & benefit–risk: ISO 14971 files, hazards/controls, and residual-risk rationale.
  • Verification & validation: Bench, biocompatibility, electrical/EMC, software validation, sterilization/packaging, and shelf life as applicable.
  • Clinical evidence: CER/CEP and PMCF (EU) or clinical data for FDA routes; literature and investigations as needed.
  • Labeling & UDI: IFU, symbols, claims, and UDI records aligned to evidence.

Process — how it works

  • 1) Define & map: Lock intended use/purpose and select the pathway (EU Annex IX–XI; US 510(k)/De Novo/PMA). Then confirm classification rules.
  • 2) Build evidence: Plan V&V and clinical work; execute tests and studies; maintain traceability to GSPRs and claims.
  • 3) Compile dossier: Assemble Annex II–III technical file (EU) or US submission (e.g., 510(k)/De Novo/PMA) with forms, summaries, and required modules.
  • 4) Submit & interact: File to NB/FDA; respond to questions (deficiencies/AI letters) with focused, cross-referenced replies.
  • 5) Authorize & register: After CE marking or FDA decision, complete registrations/listings and database entries (EUDAMED/GUDID) and release labeling.
  • 6) Maintain: Manage changes, surveillance, PSUR/PMS Reports (EU), MDR/recalls (US 21 CFR 803/806), and keep files current.

Common pitfalls

  • Claims that exceed evidence or drift from the validated intended use/purpose.
  • Weak clinical evaluation or missing PMCF rationale under MDR Annex XIV.
  • GSPR or standards mapping without objective evidence or clear “N/A” logic.
  • Software files that omit cybersecurity, SOUP control, or real-world update plans.
  • Change control gaps between submitted design and manufactured product.

Quick checks / Tips

  • Can you trace each claim → test/study → acceptance criteria → labeling?
  • Does the classification and pathway match the stated purpose and risk?
  • Are UDI, labels, and database entries consistent with the dossier?
  • Do PMS/PSUR and vigilance routes exist and link to CAPA?

FAQ

What is the difference between 510(k), De Novo, and PMA?

510(k) shows substantial equivalence to a predicate (21 CFR 807 Subpart E). De Novo creates a new Class I/II category for novel, lower-risk devices (21 CFR 860 Subpart D). PMA is for most Class III devices and requires full safety/effectiveness evidence (21 CFR 814).

Do all submissions need clinical data?

All EU devices require a clinical evaluation (Art. 61). New clinical investigations depend on risk and evidence gaps. In the US, clinical data may be required for De Novo/PMA and some 510(k)s; it depends on claims and risk.

What does a CE marking submission include?

Annex II–III technical documentation, GSPR mapping, clinical evaluation/PMCF, labeling/UDI, and QMS evidence. A Notified Body reviews most classes via Annex IX–XI.

When do changes need a new filing?

US: significant changes to intended use, technology, or risk can trigger a new 510(k) or PMA supplement (21 CFR 807.81(a)(3); 21 CFR 814.39). EU: significant changes require NB review and possible certificate updates.

How should we prepare for questions from reviewers?

Pre-index your dossier, use clear cross-references, and keep ready-to-issue responses with data tables and rationales that point to exact sections and reports.